Kushen Medina C, Sonabend Adam M, Lesniak Maciej S
Neurosurgical Oncology and The University of Chicago Brain Tumor Center, Section of Neurosurgery, The University of Chicago Hospital, 5841 South Maryland Avenue, Chicago, IL 60637, USA.
Surg Oncol Clin N Am. 2007 Oct;16(4):987-1004, xii. doi: 10.1016/j.soc.2007.07.003.
Immunotherapy has emerged as a promising tool in the management of malignant central nervous system tumors. Despite improvement in patient survival, traditional approaches, which consist mostly of surgery, radiotherapy, and chemotherapy, have been largely unsuccessful in permanently controlling these aggressive tumors. Immunotherapeutic strategies offer not only a novel approach but also an advantage in a way other modalities have been failing. Specifically, the capabilities of the immune system to recognize altered cells while leaving normal cells intact offer tremendous advantage over the conventional therapeutic approaches. This article summarizes our current understanding of immunotherapeutic treatment modalities used in clinical trials for management of malignant central nervous system tumors.
免疫疗法已成为治疗恶性中枢神经系统肿瘤的一种有前景的工具。尽管患者生存率有所提高，但主要包括手术、放疗和化疗的传统方法在永久控制这些侵袭性肿瘤方面大多未取得成功。免疫治疗策略不仅提供了一种新方法，而且在其他治疗方式失败的方面具有优势。具体而言，免疫系统识别改变的细胞同时保持正常细胞完整的能力比传统治疗方法具有巨大优势。本文总结了我们目前对用于恶性中枢神经系统肿瘤临床试验的免疫治疗方式的理解。
